share_log

藥明康德：翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

香港交易所 ·  Mar 25 06:12
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司（药明康德）於2024年3月8日至3月25日期間，通過上海證券交易所回購共計3,319,366股A股普通股，佔公司已發行股份的約0.13%。該公司於2024年3月25日亦根據2019年A股激勵計劃行使股票期權，發行了6,800股A股普通股。回購股份的價格範圍在RMB 48.22至RMB 57.32之間，而行使股票期權的發行價為RMB 38.62，均有不同程度的折讓或溢價。截至2024年3月25日，公司的已發行股本為2,546,209,943股。根據香港聯合交易所有限公司證券上市規則，公司已完成相關披露要求，並確認所有交易均獲董事會批准，並符合法律規定。
無錫藥明康德新藥開發股份有限公司（药明康德）於2024年3月8日至3月25日期間，通過上海證券交易所回購共計3,319,366股A股普通股，佔公司已發行股份的約0.13%。該公司於2024年3月25日亦根據2019年A股激勵計劃行使股票期權，發行了6,800股A股普通股。回購股份的價格範圍在RMB 48.22至RMB 57.32之間，而行使股票期權的發行價為RMB 38.62，均有不同程度的折讓或溢價。截至2024年3月25日，公司的已發行股本為2,546,209,943股。根據香港聯合交易所有限公司證券上市規則，公司已完成相關披露要求，並確認所有交易均獲董事會批准，並符合法律規定。
Between March 8 and March 25, 2024, Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. (Pharmaceutical Ming Kand) repurchased a total of 3,319,366 shares of A-shares through the Shanghai Stock Exchange, representing approximately 0.13% of the company's issued shares. On March 25, 2024, the Company also issued stock options under the 2019 A-share incentive plan and issued 6,800 shares of A common stock. The share repurchase price ranges from RMB 48.22 to RMB 57.32 and the share option issue price is RMB 38.62, with varying degrees of discount or premium. As of March 25, 2024, the issued share capital of the Company was 2,546,209,943 shares. Pursuant to the Listing Rules of the Hong Kong Stock Exchange Limited, the Company has completed the relevant disclosure requirements and confirmed that all transactions have been approved by the Board of Directors and comply with legal requirements.
Between March 8 and March 25, 2024, Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. (Pharmaceutical Ming Kand) repurchased a total of 3,319,366 shares of A-shares through the Shanghai Stock Exchange, representing approximately 0.13% of the company's issued shares. On March 25, 2024, the Company also issued stock options under the 2019 A-share incentive plan and issued 6,800 shares of A common stock. The share repurchase price ranges from RMB 48.22 to RMB 57.32 and the share option issue price is RMB 38.62, with varying degrees of discount or premium. As of March 25, 2024, the issued share capital of the Company was 2,546,209,943 shares. Pursuant to the Listing Rules of the Hong Kong Stock Exchange Limited, the Company has completed the relevant disclosure requirements and confirmed that all transactions have been approved by the Board of Directors and comply with legal requirements.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more